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EXERCISE-INDUCED  
PULMONARY HEMORRHAGE 
The first record of exercise-induced pulmonary hemorrhage (EIPH) or bleeding is 
by the Elizabethan author and horse breeder Gervase Markham, who notes in one of 
his books on horsemanship in the late 1500s, in good Elizabethan English, that:
 “Many horfes [efpecially young horfes] are often fubject to this Bleeding at 
the Nofe, which I imagine proceedeth either from the much abundance of Blood, or 
that the Vein, which endeth in that Place is either broken, fretted or opened.”
Markham was describing the post-exercise presentation of blood at the 
nostrils, the obvious presentation of what we now know as EIPH. Horsemen had 
long suspected that horses also bled into their lungs during vigorous exercise, 
but visualization of such internal bleeding required development of the fiberop-
tic endoscope.
As long ago as the early 1700s, when the foundation sires of the Thor-
oughbred breed were racing and breeding, EIPH was recognized as epistaxis, or 
bleeding from the nose. One of the most prolific sires was Bartlett’s Childers, 
also known as Bleeding Childers for his propensity to bleed from the nose. 
Bartlett’s Childers was unraced but distinguished himself as the great-great-
grandsire of Eclipse, who is represented in the pedigree of every modern-day 
Thoroughbred. The flexible fiberoptic endoscope that came into use in the 1970s 
led to the discovery that a high percentage of exercised horses showed varying 
degrees of bleeding in their windpipes following strenuous exercise. What had 
been observed for centuries—post-race bleeding from the nose—had only been 
the tip of the iceberg, accounting for about 4 percent of EIPH cases.
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EIPH is a hemorrhage that occurs in the lungs of animals, including horses, 
camels and greyhounds, and even in elite human athletes during strenuous exercise. 
In horses, this hemorrhage occurs in polo horses, show and event horses, barrel 
racing horses and any other equine athletes participating in any endeavor in which 
strenuous exercise is required. Airway examination suggests that almost all race-
horses experience some degree of EIPH—50 percent to 95 percent with well over 90 
percent of horses showing blood in their tracheas at some time in their careers. 
This hemorrhage occurs when the thin membrane between the capillaries 
and alveolar air sacs fails due to the pressure within the pulmonary capillaries 
of the lung. The blood in the lungs, along with the damage from the ruptured 
capillaries, results in inflammation that heals with scarring, and the dam-
aged lung tissue loses its natural ability to expand and contract. The disease 
is progressive and cumulative, with the scientifically demonstrated result of 
permanent lesions in the lungs. 
In most initial cases, the hemorrhage is slight, but as more capillaries fail, 
the bleeding can be marked, even resulting at times in acute fatal hemorrhage. 
In extreme cases, the bleeding from the lungs can result in blood coming out 
of the nostrils as the horse runs. In this situation, the horse is in danger of fal-
tering, thus endangering itself, its rider and the other horses and riders. In the 
past, before Lasix was approved for use, horses died acutely on the racetrack 
from EIPH. With the advent of using Lasix in horse racing, the incidence of these 
catastrophic events has been significantly reduced. 
CAUSES OF EIPH
EIPH is caused by stress failure or the rupture of pulmonary capillaries 
because of the high pulmonary capillary pressures that occur during strenuous 
exercise. It remains one of the most researched conditions of the racehorse, and 
the preponderance of the scientific literature has revealed the following:
1.	 When EIPH is not controlled, a cycle of hemorrhage, inflammatory 
reaction and more hemorrhage occurs.
2.	 EIPH may occur at any age.
3.	 EIPH has not been established to be an inherited trait.
4.	 EIPH occurs with high frequency in both sexes.
DIAGNOSIS OF EIPH
EIPH presents in a number of ways, including the following:
Bleeding from the nose (epistaxis): Readily obvious and recognized  
historically, even before the inception of the Thoroughbred breed in the 1700s. 
May be observable in up to 4 percent of horses post-exercise. 
Blood in the trachea: Readily observed by post-race endoscopic examina-
tion of the trachea. The flexible fiberoptic endoscope permits visual examination 
of the respiratory tract down into the major bronchi to each lung. All racetrack 
veterinarians carry a flexible endoscope, and this is the most common means of 
evaluation of both the upper airway and lungs of the horse.
Microscopic evidence of hemorrhage: Broncho alveolar lavage fluid (BAL) 
collection involves injecting sterile fluid into the bronchi followed by collecting 
this fluid to be examined microscopically. This procedure detects the subtlest 
form of EIPH: minimal bleeding not observable by endoscopic examination. 
Essentially 100 percent of horses in training test BAL positive for EIPH. 
Post-mortem examination: In a small fraction of cases, horses bleed acute-
ly into their lungs and die on the racetrack, sometimes with no obvious evidence 
of blood at the nostrils. EIPH has been reported as being the cause of between 
50 percent and 80 percent of acute non-musculoskeletal injury-driven deaths in 
racehorses. Because blood may not be apparent at the nostrils, a full necropsy 
is required to definitively identify cases of acute death caused by EIPH. 
 CONTROL AND TREATMENT  
OF EIPH
Control is by far the best approach to EIPH, and the best method of EIPH 
control is pre-exercise administration of the diuretic Lasix. Administration of 
Lasix pre-exercise has been definitively shown to decrease the incidence and 
severity of EIPH. In 2009 gold standard-quality research by Australian professor 
Ken W. Hinchcliff and colleagues showed that Lasix decreases the incidence and 
severity of EIPH, findings the American College of Veterinary Internal Medicine 
concurred with. 
No control measure for EIPH has been studied to the same extent as Lasix. 
Many others have been tried, including medications that enhance clotting, 
improve capillary stability or decrease blood clot reduction. Of those medica-
tions, most have failed to demonstrate effectiveness. Once it was discovered 
that Lasix helps to prevent EIPH, some horsemen began to withhold water for up 
to 24 hours before racing or strenuous training. There is no scientific evidence 
that this practice is effective, and it could be considered inhumane. Concern 
also remains that this practice may be used in countries where race-day Lasix 
is not permitted and may be a significant part of plan B approaches to EIPH in 
jurisdictions that choose to ban Lasix.
Once EIPH has occurred, treatment is directed at controlling the inflam-
mation and clearing the blood and inflammatory debris from the lungs. Some 
veterinarians prescribe antibiotics to prevent bacterial colonization of the blood, 
bronchodilators to aid in removal of the blood and even hyperbaric oxygen 
therapy to accelerate healing. If severe enough, lung rest, such as restricting 
fast exercise, is required during the healing process.
WHAT IS LASIX?
Lasix is a short-acting diuretic, or “water pill,” patented in 1959 and 
approved for use in 1964. It is used most commonly for swelling or edema 
resulting from heart failure or liver or kidney disease, as well as high blood 
pressure. It is on the World Health Organization’s list of essential medicines as 
one of the most effective and safe medications needed in a health system. Tens 
of millions of people take this medication daily. Lasix has also been used to 
prevent EIPH in horses for more than 40 years, and approximately 90 percent of 
horses running in North America are administered this preventative medication 
before racing. Lasix is recommended by every major U.S. veterinary organization 
to protect the health and welfare of the racehorse. 
The effect of Lasix when administered intravenously peaks at 30 minutes, 
with return of the urine to pre-Lasix concentrations within about 2 ½ hours. 
Lasix reduces right atrial blood pressure for up to three hours post- 
administration and lowers pulmonary capillary blood pressure for up to four 
hours post-administration. For its protective effect, Lasix must be administered 
on race day and no more than four hours before the race. Dehydration due to 
Lasix is minimal, and return to normal values occurs even before the strenuous 
exercise or race occurs.
THE HISTORY OF LASIX  
USE IN AMERICAN HORSE RACING 
It has long been rumored that the then-recently FDA-approved diuretic 
Lasix was used to control EIPH in Northern Dancer’s victory in the 1964 Kentucky 
Derby. A decade later, in 1974, the use of Lasix was legalized on race day in 
Maryland. Two years later, a committee led by Dr. Al Gabel of the American 
Association of Equine Practitioners reported to the National Association of 
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being used in the prevention of epistaxis. 
This initial use of furosemide was based on 
clinical experience and, until recently, there 
On the other hand, most American racing 
states have long since approved the use of 
furosemide on race day for the prevention/
alleviation of epistaxis, now known to be 
a component of Exercise-Induced Pulmo-
nary Hemorrhage [EIPH]. Very recently, 
however, questions have been raised about 
whether or not the routine pre-race treatment 
of racing horses with furosemide for the pre-
vention of epistaxis/EIPH passes “the smell 
test,”2 which has led to renewed examination 
furosemide in North American racing.
We now draw attention to some clini-
cal evidence establishing, in large numbers 
in reducing the incidence of epistaxis. 
Mr. Bill Heller in his monograph on Lasix, 
“Run, Baby, Run,”3 where these data have 
remained hidden in plain sight since the 
2002 publication of this book. Reviewing 
this book  as part of an overall review of 
the literature on furosemide in the horse, 
we noted, on pages 112 and 113, a table 
entitled “New York By The Numbers, Cases 
of Epistaxis,” dated 1992 to 2001.  Inspec-
dramatic reduction in the incidence of EIPH 
in New York racing following the 1995 
approval of furosemide.  We now present 
this data in standard graphical format  (Fig 
of furosemide in reducing the incidence of 
epistaxis in horses racing in New York in the 
6 years and 4 months immediately following 
approval of furosemide in New York racing.
In analyzing these data we note the 
-
ing (“dripping of blood”) from the nose, 
Epistaxis is, however, only one manifesta-
tion of what is now known as Exercise-
Induced Pulmonary Hemorrhage (EIPH).4 
It is also the only manifestation of EIPH 
observable without special equipment, and 
Epistaxis and Related Considerations  
Figure 1 Effect of Furosemide on Epistaxis Cases/Year in New York Racing
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EPISTAXIS CASES IN NEW YORK PRE- AND POST-LASIX APPROVAL
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State Racing Commissioners that Lasix “helped prevent epistaxis” and that 
“in many cases it restores normal performance of horses which bleed.” With 
strong support from the veterinary and racing community, all U.S. racing 
jurisdictions, except for New York, rapidly adopted a three- to four-hour pre-
race Lasix rule. As the last holdout state, New York finally adopted the rule in 
1995 and immediately saw a nearly 80 percent decrease in the incidence of 
post-race epistaxis (See chart below).
LASIX’S EFFECT ON THE ABILITY 
TO DETECT DRUGS
In human drug testing, diuretics present a significant concern as masking 
or diluting agents. This is because most drug testing in humans is performed 
on urine samples, and anything that dilutes the urine may well dilute prohibit-
ed substances to the point of making them undetectable. Horse racing shared 
this concern when Lasix use was being adopted many decades ago, but the 
racing industry addressed the issue by establishing the four-hour rule, whereby 
Lasix was administered intravenously at four hours before a race. As stated 
earlier, the diuretic effect abates about 2 ½ hours after administration, leaving 
a full 1 ½ hours before the horse goes to post. Most states now regulate 
that Lasix must be administered by veterinarians employed by a regulatory 
authority rather than by private practitioners. In addition to the four-hour rule, 
drug testing in horses has moved away from urine-based testing to blood 
testing, which also helps since Lasix has no significant effect on the detection 
of substances in blood. 
IS LASIX PERFORMANCE- 
ENHANCING?
Some have claimed that Lasix is performance-enhancing, so let’s review a 
few things:
• EIPH has clearly been shown to negatively affect the performance of 
a horse, a fact that is not hard to understand given that blood in the 
lungs can dramatically interfere with a horse’s ability to use oxygen. 
• Numerous scientific studies have shown that Lasix decreases the 
severity of EIPH.
• The majority of horses performing at maximal exertion will experience 
EIPH at some time or another.
• It is therefore not surprising that when studies have looked specifi-
cally at the performance of horses racing with Lasix, the medication 
was associated with better performance. 
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Does Lasix improve performance if there is no EIPH? Only a few studies 
have been designed to answer this question.
A study using tracheobronchoscopy found that male and female horses that 
did not bleed with or without Lasix had no performance enhancement from the 
administration of the medication, but geldings (castrated males) did. However, 
in that study, horses were raced first without Lasix, raced next with Lasix and 
then raced again without Lasix. Out of the 665 horses initially examined, only 
79 exhibited no EIPH over the three races. Of those, only a group of 18 geldings 
demonstrated improved performance when Lasix was added. Curiously, in the 
third race, when the same geldings raced without Lasix, their form did not 
return to the original no-Lasix performance, indicating that the improvement in 
the second race was unlikely to be related to the administration of Lasix.
Another study was performed on a treadmill using oxygen consumption as 
a measure of performance. Because oxygen is used to generate energy, this is 
commonly equated to performance. This study found that Lasix made the horses 
lose weight and that the oxygen consumption per pound improved—but not 
the overall oxygen consumption per horse! Since races are run by whole horses, 
and not by the pound, this is further evidence that Lasix does not enhance 
performance, aside from its effect on reducing EIPH.
WHY DOES THE “NEW WORLD”  
ALLOW THE USE OF LASIX ON 
RACE DAY?
In countries where EIPH is often identified only through nasal bleeding, only 4 
percent of actual EIPH cases are identified. Fortunately for the horse, the trainers 
in those countries do realize the benefits of using Lasix in training their horses. 
However, they are not allowed to use Lasix on race day—when the horse is going 
to have to give maximum effort. International markets for prospective racehorses 
often claim that their horses are superior because they race free of Lasix and EIPH, 
but despite this claim, American Thoroughbred bloodlines continue to dominate 
throughout the world. Further, many of the most prominent buyers of American 
horses are people that race outside this country. Not recognizing the proven 
high incidence of EIPH is one thing, but to also ignore the mounting evidence 
that, uncontrolled, EIPH can lead to chronic, progressive lung pathology appears 
hypocritical and is largely unacceptable to the trainers, veterinarians and most of 
the owners in North America. This statement is backed by a National Horsemen’s 
Benevolent & Protective Association poll in which more than 90 percent of the 
owners and trainers were in favor of the use of Lasix on the day of the race. The 
North American racing industry is the largest racing industry in the world by far. 
To capitulate to the balance of the “Old World” is a little like the tail wagging 
the dog, especially in light of the substantial scientific evidence supporting the 
benefits of Lasix to the equine athlete.
WHY SHOULD HORSE RACING  
AND OTHER USES OF THE HORSE IN 
WHICH STRENUOUS EXERCISE IS 
REQUIRED REMAIN A VIABLE  
COMPONENT OF OUR SOCIETY?
According to the 2017 Economic Impact Study of the American Horse Coun-
cil, in the United States, more than $50 billion is directly attributable to horses, 
and including indirect effects, the contribution is more than $122 billion. Direct 
employment in the horse industry is almost 500,000 full-time jobs, and the indi-
rect impact contributes more than 1.7 million jobs. Green space preservation 
provided by the horse industry totals 81 million acres, including 32 million acres 
of deeded land and 49 million acres of land leased for horse-related activities.
Therefore, despite the average American having minimal direct interaction 
with horses, these animals continue to significantly impact the lives of us all. 
Those directly involved in the horse racing industry are in awe of these magnif-
icent athletes. Through gambling, entertainment and the sheer enjoyment of 
watching the most elite of athletes perform, all while preserving green space, 
often in metropolitan areas where such space is limited, horse racing provides 
all Americans with valuable benefits.
THE PROBLEM, IN OUR OPINION
Modern medicine has greatly benefited mankind. In human medicine, infant 
mortality has fallen by 60 percent since the time Lasix was introduced in horse 
racing, and human life expectancy has increased from 55 to 75 years during 
that time. These improvements in human health are due, in part, to modern 
medicine and health care. 
Advances in veterinary medicine, such as the introduction of the flexible 
fiberoptic endoscope, have paralleled the advances in human health. Advocates 
for severe restrictions on medications for racehorses would have medical deci-
sions for our cherished athletes made not by the animal’s own veterinarian in 
consultation with the owner and trainer but by administrators in a corner office, 
guided by perceptions and traditions of the Old World. This would be absurd and 
cruel, just as it would be to deprive any animal or human of the benefits that 
modern medicine makes possible. 
Modern therapeutic medications do not enhance performance, nor do they 
contribute in any way to adverse events occurring at the racetrack. Therapeutic 
medications improve horses’ quality of life, and arguments to restrict such 
medications direct precious resources away from investigation of the true causes 
of some of our industry’s problems. The medication of racehorses is more strictly 
regulated than medications for human athletes or for those entrusted with our 
safety such as airline pilots, ship captains and bus drivers. And yet some unrea-
sonable individuals and organizations attempt to restrict medication even further. 
They seem to forget or do not recognize that a racehorse is an athlete.
An example of this “blame the medication” mentality is the recent response 
to the injuries at Santa Anita Park in California. It is disingenuous and mis-
leading to suggest that the use of race-day Lasix was in any way associated 
with these injuries; in fact, if anything, Lasix decreases the likelihood of injury 
to both the racehorse and the jockey. Santa Anita did not have the increase in 
injuries in the past, and the trainers, veterinarians and apparently some other 
racetrack personnel were the same. If the weather was a factor, it was more 
likely related to how the track was maintained during the rainy weather and 
not the weather itself since Los Alamitos (less than 30 miles away) and Golden 
Gate, located in the same state and receiving about the same rainfall, did not 
experience similar increases in injuries. 
If a stretch of highway is associated with excessive fatalities, we send out a 
team of engineers to determine how that stretch differs from other, safer roads. 
Then the road is modified in response to the investigation. This cannot guarantee 
that no fatalities will ever occur there, but it does return the safety to the same 
level as any other stretch of highway. The same type of investigation needs to 
be conducted every time there is any spike in severe injuries on a racetrack. The 
racing surface, the track base, the cushion and how it is managed in the face of 
weather all require careful evaluation. Such investigation should include all facets 
of the industry: horsemen, jockeys, racehorse veterinarians and track managers. 
One thing is certain—Lasix, in use for 40 years at every racetrack in California, 
had no role in that two-month spike in injuries at Santa Anita.
For more information on the facts concerning Lasix and EIPH, visit  
lasixeiphfacts.com. HJ
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